Optimal Chemotherapy of Ovarian Cancer with an Old Regimen

References

• Omura G A, Morrow C P, Blessing J A, et al. A randomized comparison of melphalan versus melphalan plus hexa-methylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 1983; 51: 783–9
   PubMed Web of Science ®Google Scholar
• Tropé C. Melphalan with and without doxorubicin in advanced ovarian cancer. Obstet Gynecol 1987; 70: 582–6
   PubMed Web of Science ®Google Scholar
• Stewart L A. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 1991; 303: 884–93
   PubMed Web of Science ®Google Scholar
• Omura G, Blessing J A, Ehrlich C E, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. Cancer 1986; 57: 1725–30
   PubMed Web of Science ®Google Scholar
• Omura G A, Brady M F, Homesley H D, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138–50
   PubMed Web of Science ®Google Scholar
• Neijt J P, ten Bokkel Huinink W W, van der Burg M E, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984; 2: 594–600
   PubMed Web of Science ®Google Scholar
• Neijt J P, ten Bokkel Huinink W W, van der Burg M EL, et al. Long-term survival in ovarian cancer. Eur J Cancer 1991; 27: 1367–72
   PubMed Web of Science ®Google Scholar
• Gruppo Interregionale Cooperativo Oncologico Gineco-logia. Randomised comparison of cis-platin with cyclo-phosphamide/cis-platin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 1987; 2: 353–9
   PubMedGoogle Scholar
• Gruppo Interregionale Cooperativo Oncologico Gineco-logia Italy. Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. Gynecol Oncol 1992; 45: 115–7
   PubMed Web of Science ®Google Scholar
• Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J, Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 1986; 4: 722–9
   PubMed Web of Science ®Google Scholar
• Conte P F, Bruzzone M, Chlara S, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965–71
   PubMed Web of Science ®Google Scholar
• Bertelsen K, Jakobsen A, Andersen J E, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28: 161–9
   PubMed Web of Science ®Google Scholar
• Omura G A, Bundy B N, Berek J S, Curry S, Delgodo G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 1989; 7: 457–65
   PubMed Web of Science ®Google Scholar
• Omura G A. Meta-analysis project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a metaanalysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991; 9: 1668–74
   PubMed Web of Science ®Google Scholar
• Levin L, Hryniuk W M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756–67
   PubMed Web of Science ®Google Scholar
• McGuire W P, Hoskins W J, Brady M S, Homesly H D, Clarke-Pearson D L, the Gynecologic Oncology Group 606. A phase III trial of dose intense (Dl) versus standard dose (DS) cisplatin (CDDP) and Cytoxan (CTX) in advanced ovarian cancer (AOC) (Abstract). Int Gyn Cancer Soc Third Biennial Meeting, CairnsAustralia, September, 22–261991
   Google Scholar
• Kaye S, Lewis C R, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329–33
   PubMed Web of Science ®Google Scholar
• Colombo N, Pittelll M R, Parma G. Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventinal dose (DC) vs dose-intense (Dl) cisplatin chemotherapy. ASCO 1993; 15: 255
   Google Scholar
• Vermorken J B, ten Bokkel Huinink W W, Eisenhauer E A, et al. Carboplatin versus cisplatin. Ann Oncol 1993; 4: 41–8
   PubMed Web of Science ®Google Scholar
• Belpomme D, Bugat R, Rives M, et al. Carboplatin versus cisplatin in association with cyclophosphamide and doxorubicin as first line therapy in stage III-IV ovarian carcinoma: results of an artac phase III trial. ASCO 1992; 11: 227
   Google Scholar
• Edmonson J H, McCormack G M, Wieand H S, et al. Cyclo-phosphamide-Cisplatin versus cyclophosphamide-Carboplatin in stage III-IV ovarian carcinoma: A comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989; 81: 1500–4
   PubMedGoogle Scholar
• de Vries E GE, Hamilton T C, Llnd M, Dauplat J, Neijt J P, Ozols R F. Drug resistance, supportive care and dose intensity. Ann Oncol 1993; 4: 57–62
   PubMed Web of Science ®Google Scholar
• Hakes T B, Chalas E, Hoskins W J, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 45: 284–9
   PubMed Web of Science ®Google Scholar
• Bertelsen K, Jakobsen A, Strøyer I, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group Trial (DACOVA). Gynecol Oncol 1993; 49: 30–6
   PubMed Web of Science ®Google Scholar